Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

Luca Laurenti, Antonio Cuneo, Monia Marchetti, Giovanni Barosi, Atto Billio, Maura Brugiatelli, Stefania Ciolli, Francesca Romana Mauro, Stefano Molica, Marco Montillo, Pierluigi Zinzani, Sante Tura

Risultato della ricerca: Contributo in rivistaArticolo in rivista

9 Citazioni (Scopus)

Abstract

By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.
Lingua originaleEnglish
pagine (da-a)1269-1277
Numero di pagine9
RivistaLeukemia Research
Volume38
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Bendamustine
  • Chronic lymphocytic leukemia
  • First line treatment
  • Guidelines

Fingerprint

Entra nei temi di ricerca di 'Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group'. Insieme formano una fingerprint unica.

Cita questo